Community Health Systems (CYH) Financials

Community Health Systems logo
$1.62 +0.02 (+0.93%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$1.77 +0.14 (+8.80%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Community Health Systems

Annual Income Statements for Community Health Systems

This table shows Community Health Systems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
158 -1,721 -2,459 -788 -675 511 230 46 -133 -516 509
Consolidated Net Income / (Loss)
259 -1,626 -2,396 -704 -590 607 368 179 16 -362 676
Net Income / (Loss) Continuing Operations
295 -1,611 -2,384 -704 -590 607 368 179 16 -362 676
Total Pre-Tax Income
411 -1,715 -2,833 -715 -430 422 499 349 207 -283 724
Total Operating Income
1,337 -860 -1,878 208 650 1,126 1,402 821 957 542 1,488
Total Gross Profit
10,446 6,803 5,305 5,416 5,112 4,689 5,084 4,589 5,082 5,270 5,209
Total Revenue
22,564 18,438 15,353 14,155 13,210 12,390 12,368 12,211 12,490 12,634 12,485
Operating Revenue
22,564 18,438 15,353 14,155 13,210 12,390 12,368 12,211 12,490 12,634 12,485
Total Cost of Revenue
12,118 11,635 10,048 8,739 8,098 7,701 7,284 7,622 7,408 7,364 7,276
Operating Cost of Revenue
8,991 11,635 10,048 8,739 8,098 7,701 7,284 7,622 7,408 7,364 7,276
Total Operating Expenses
9,109 7,663 7,183 5,208 4,462 3,563 3,682 3,768 4,125 4,728 3,721
Selling, General & Admin Expense
4,520 4,248 3,864 3,496 3,303 2,957 2,958 3,336 3,388 3,642 3,424
Depreciation Expense
1,172 1,100 861 700 608 558 540 534 505 486 426
Other Operating Expenses / (Income)
3,345 380 366 333 320 - 160 -173 319 299 277
Impairment Charge
68 1,919 2,123 668 138 48 24 71 -87 301 -406
Total Other Income / (Expense), net
-926 -855 -955 -923 -1,080 -704 -903 -472 -750 -825 -764
Interest Expense
16 30 40 -31 54 -317 79 -253 -72 -25 -97
Interest & Investment Income
-910 -825 -915 -954 -1,026 -1,021 -824 -844 -822 -850 -861
Income Tax Expense
116 -104 -449 -11 160 -185 131 170 191 79 48
Net Income / (Loss) Attributable to Noncontrolling Interest
101 95 63 84 85 96 138 133 149 154 167
Basic Earnings per Share
$1.38 ($15.54) ($22.00) ($6.99) ($5.93) $4.43 $1.82 $0.35 ($1.02) ($3.90) $3.81
Weighted Average Basic Shares Outstanding
114.45M 110.73M 111.77M 112.73M 113.74M 115.49M 126.75M 128.81M 130.45M 132.10M 133.56M
Diluted Earnings per Share
$1.37 ($15.54) ($22.00) ($6.99) ($5.93) $4.39 $1.76 $0.35 ($1.02) ($3.90) $3.77
Weighted Average Diluted Shares Outstanding
115.27M 110.73M 111.77M 112.73M 113.74M 116.54M 130.60M 130.06M 130.45M 132.10M 135.01M
Weighted Average Basic & Diluted Shares Outstanding
114.50M 110.70M 111.80M 112.70M 117.86M 129.62M 132.12M 134.70M 136.74M 138.92M 138.63M

Quarterly Income Statements for Community Health Systems

This table shows Community Health Systems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-41 -13 -391 -71 -13 282 130 110 -58 70 -86
Consolidated Net Income / (Loss)
-6.00 26 -355 -27 25 320 171 160 -25 104 -50
Net Income / (Loss) Continuing Operations
-6.00 26 -355 -27 25 320 171 160 -25 104 -50
Total Pre-Tax Income
22 50 -419 64 67 438 -2.00 221 64 180 -53
Total Operating Income
231 238 -205 278 284 512 243 449 281 389 146
Total Gross Profit
1,285 1,328 1,262 1,169 1,298 1,337 1,271 1,303 1,202 1,187 1,137
Total Revenue
3,140 3,140 3,090 3,264 3,159 3,133 3,087 3,106 2,965 2,825 2,757
Operating Revenue
3,140 3,140 3,090 3,264 3,159 3,133 3,087 3,106 2,965 2,825 2,757
Total Cost of Revenue
1,855 1,812 1,828 2,095 1,861 1,796 1,816 1,803 1,763 1,638 1,620
Operating Cost of Revenue
1,855 1,812 1,828 2,095 1,861 1,796 1,816 1,803 1,763 1,638 1,620
Total Operating Expenses
1,054 1,090 1,467 891 1,014 825 1,028 854 921 798 991
Selling, General & Admin Expense
845 882 1,010 905 865 885 832 842 828 799 809
Depreciation Expense
115 125 117 129 105 105 108 108 114 108 106
Other Operating Expenses / (Income)
77 73 73 -150 68 74 67 68 69 63 62
Impairment Charge
17 10 267 7.00 -24 -239 21 -164 -90 -172 14
Total Other Income / (Expense), net
-209 -188 -214 -214 -217 -74 -245 -228 -217 -209 -199
Interest Expense
0.00 -26 0.00 1.00 0.00 -138 33 8.00 8.00 5.00 0.00
Interest & Investment Income
-209 -214 -214 -213 -217 -212 -212 -220 -209 -204 -199
Income Tax Expense
28 24 -64 91 42 118 -173 61 89 76 -3.00
Net Income / (Loss) Attributable to Noncontrolling Interest
35 39 36 44 38 38 41 50 33 34 36
Basic Earnings per Share
($0.32) ($0.10) ($2.95) ($0.53) ($0.10) $2.11 $0.97 $0.83 ($0.43) $0.51 ($0.63)
Weighted Average Basic Shares Outstanding
131.27M 132.34M 132.38M 132.10M 132.88M 133.76M 133.79M 133.56M 134.42M 135.49M 135.54M
Diluted Earnings per Share
($0.32) ($0.10) ($2.95) ($0.53) ($0.10) $2.09 $0.96 $0.82 ($0.43) $0.51 ($0.63)
Weighted Average Diluted Shares Outstanding
131.27M 132.34M 132.38M 132.10M 132.88M 134.88M 135.19M 135.01M 134.42M 136.51M 135.54M
Weighted Average Basic & Diluted Shares Outstanding
138.97M 138.94M 138.95M 138.92M 140.31M 140.12M 138.52M 138.63M 140.92M 141.01M 141.03M

Annual Cash Flow Statements for Community Health Systems

This table details how cash moves in and out of Community Health Systems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-325 54 325 -367 20 1,460 -1,169 -389 -80 -1.00 223
Net Cash From Operating Activities
921 1,137 773 274 385 2,178 -131 300 210 480 543
Net Cash From Continuing Operating Activities
921 1,137 773 274 385 2,178 -131 300 210 480 543
Net Income / (Loss) Continuing Operations
259 -1,626 -2,396 -704 -590 607 368 179 16 -362 676
Consolidated Net Income / (Loss)
259 -1,626 -2,396 -704 -590 607 368 179 16 -362 676
Depreciation Expense
1,174 1,100 861 700 608 558 540 534 505 486 426
Non-Cash Adjustments To Reconcile Net Income
203 1,956 2,237 433 435 -202 167 -99 44 481 -319
Changes in Operating Assets and Liabilities, net
-715 -293 71 -155 -68 1,215 -1,206 -314 -355 -125 -240
Net Cash From Investing Activities
-1,051 630 1,069 -245 -2.00 177 -524 -259 -26 -275 847
Net Cash From Continuing Investing Activities
-1,051 630 1,069 -245 -2.00 177 -524 -259 -26 -275 847
Purchase of Property, Plant & Equipment
-953 -744 -564 -527 -438 -440 -469 -415 -467 -360 -335
Acquisitions
-57 -123 -6.00 -26 -27 -2.00 -10 -28 -49 -34 -1.00
Purchase of Investments
-162 -505 -125 -78 -80 -178 -171 -114 -137 -81 -139
Sale of Property, Plant & Equipment
15 15 7.00 8.00 3.00 4.00 10 38 28 5.00 8.00
Divestitures
155 546 1,692 405 604 648 127 89 432 174 1,254
Sale and/or Maturity of Investments
156 1,683 208 114 92 194 102 231 232 80 123
Other Investing Activities, net
-205 -242 -143 -141 -156 -49 -113 -60 -65 -59 -63
Net Cash From Financing Activities
-195 -1,713 -1,517 -396 -363 -895 -514 -430 -264 -206 -1,167
Net Cash From Continuing Financing Activities
-195 -1,713 -1,517 -396 -363 -895 -514 -430 -264 -206 -1,167
Repayment of Debt
-5,080 -6,741 -5,457 -2,129 -3,603 -5,649 -4,739 -2,430 -4,327 -5,072 -6,532
Payment of Dividends
-136 -111 -106 -127 -110 -117 -140 -130 -142 -158 -167
Issuance of Debt
5,128 5,145 4,046 1,858 3,281 4,855 4,370 2,125 4,204 5,024 5,532
Issuance of Common Equity
- - 5.00 3.00 10 15 0.00 13 5.00 1.00 2.00
Other Financing Activities, net
52 -6.00 -5.00 -1.00 59 1.00 -5.00 -8.00 -4.00 -1.00 -2.00
Cash Interest Paid
925 930 852 936 1,011 1,039 778 835 801 741 804
Cash Income Taxes Paid
12 16 -4.00 19 3.00 -2.00 -4.00 -6.00 91 171 249

Quarterly Cash Flow Statements for Community Health Systems

This table details how cash moves in and out of Community Health Systems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
10 -9.00 -6.00 4.00 394 25 -333 137 452 -563 6.00
Net Cash From Operating Activities
96 101 67 216 120 88 69 266 -297 88 154
Net Cash From Continuing Operating Activities
96 101 67 216 120 88 69 266 -297 88 154
Net Income / (Loss) Continuing Operations
-6.00 26 -354 -28 25 320 171 160 -25 104 -51
Consolidated Net Income / (Loss)
-6.00 26 -354 -28 25 320 171 160 -25 104 -51
Depreciation Expense
115 126 116 129 105 106 106 109 114 108 106
Non-Cash Adjustments To Reconcile Net Income
56 47 320 58 25 -327 96 -113 -39 -126 54
Changes in Operating Assets and Liabilities, net
-69 -98 -15 57 -35 -11 -304 110 -347 2.00 45
Net Cash From Investing Activities
-99 -108 75 -143 444 342 -81 142 1,023 -23 -106
Net Cash From Continuing Investing Activities
-99 -108 75 -143 444 342 -81 142 1,023 -23 -106
Purchase of Property, Plant & Equipment
-93 -88 -70 -109 -85 -91 -65 -94 -76 -76 -87
Acquisitions
-5.00 - - -29 0.00 - -1.00 - -5.00 -49 -1.00
Purchase of Investments
-4.00 -19 -31 -27 -22 -50 -35 -32 -42 -23 -22
Divestitures
0.00 - 174 - 563 450 -1.00 242 1,108 110 -8.00
Sale and/or Maturity of Investments
12 20 22 26 23 35 29 36 45 18 17
Other Investing Activities, net
-10 -24 -21 -4.00 -35 -7.00 -11 -10 -7.00 -3.00 -5.00
Net Cash From Financing Activities
13 -2.00 -148 -69 -170 -405 -321 -271 -274 -628 -42
Net Cash From Continuing Financing Activities
13 -2.00 -148 -69 -170 -405 -321 -271 -274 -628 -42
Repayment of Debt
-885 -2,237 -806 -1,144 -1,088 -2,294 -2,899 -251 -358 -1,195 -606
Payment of Dividends
-50 -36 -38 -34 -35 -61 -26 -45 -57 -33 -39
Issuance of Debt
950 2,270 696 1,108 954 1,950 2,603 25 143 600 602
Issuance of Common Equity
0.00 1.00 - - 0.00 1.00 1.00 - 0.00 - 1.00
Cash Interest Paid
149 211 202 179 229 178 215 182 261 176 213
Cash Income Taxes Paid
0.00 -84 -48 -39 80 -181 -91 441 0.00 61 15

Annual Balance Sheets for Community Health Systems

This table presents Community Health Systems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
26,595 21,944 17,450 15,859 15,609 16,006 15,217 14,669 14,455 14,054 13,204
Total Current Assets
5,166 4,666 4,068 3,549 3,427 4,510 3,479 3,082 3,208 3,301 3,234
Cash & Equivalents
184 238 563 196 216 1,676 507 118 38 37 260
Accounts Receivable
3,611 3,176 2,384 2,352 2,258 1,927 2,062 2,040 2,231 2,286 2,077
Inventories, net
580 480 444 402 354 335 355 353 328 331 322
Prepaid Expenses
197 187 198 196 193 184 192 237 260 236 181
Current Deferred & Refundable Income Taxes
27 17 17 3.00 48 50 94 99 76 53 13
Other Current Assets
567 568 462 400 358 338 269 235 275 358 381
Plant, Property, & Equipment, net
10,112 8,149 7,052 6,139 5,608 5,322 5,553 5,365 5,207 4,776 4,503
Plant, Property & Equipment, gross
14,906 12,422 11,497 10,301 9,653 9,352 19,514 9,639 9,511 9,160 8,912
Accumulated Depreciation
4,794 4,273 4,445 4,162 4,045 4,030 4,204 4,274 4,304 4,384 4,409
Total Noncurrent Assets
11,317 9,129 6,330 6,171 6,574 6,174 6,185 6,222 6,040 5,977 5,467
Goodwill
8,965 6,521 4,723 4,559 4,328 4,219 4,219 4,166 3,958 3,789 3,316
Noncurrent Deferred & Refundable Income Taxes
- 15 62 69 38 59 53 49 29 13 50
Other Noncurrent Operating Assets
2,352 2,593 1,545 1,543 2,208 1,896 1,913 2,007 2,053 2,175 2,101
Total Liabilities & Shareholders' Equity
26,595 21,944 17,450 15,859 15,609 16,006 15,217 14,669 14,455 14,054 13,204
Total Liabilities
21,919 19,662 17,615 16,818 17,248 17,060 16,027 15,403 15,279 15,371 14,041
Total Current Liabilities
3,072 2,887 2,356 2,392 2,282 2,815 2,364 2,186 2,142 2,345 2,208
Short-Term Debt
229 455 33 204 20 123 31 21 21 20 16
Accounts Payable
1,258 995 967 887 811 783 830 773 912 913 842
Accrued Expenses
535 499 442 468 532 980 476 418 354 479 433
Current Deferred & Payable Income Tax Liabilities
- - - - - - - - - - 0.00
Current Employee Benefit Liabilities
823 731 685 627 594 637 655 637 571 596 569
Other Current Liabilities
- - - - 136 142 147 148 124 115 110
Other Current Nonoperating Liabilities
227 207 229 206 189 150 225 189 160 222 238
Total Noncurrent Liabilities
18,847 16,775 15,259 14,426 14,966 14,245 13,663 13,217 13,137 13,026 11,833
Long-Term Debt
16,556 14,789 13,880 13,392 13,385 12,093 12,109 11,614 11,466 11,432 10,380
Noncurrent Deferred & Payable Income Tax Liabilities
593 411 19 26 200 29 192 354 369 231 25
Other Noncurrent Operating Liabilities
1,698 1,575 1,360 1,008 1,381 2,123 827 1,249 1,302 1,363 1,428
Redeemable Noncontrolling Interest
571 554 527 504 502 484 480 541 323 359 322
Total Equity & Noncontrolling Interests
4,105 1,728 -692 -1,463 -2,141 -1,538 -1,290 -1,275 -1,147 -1,676 -1,159
Total Preferred & Common Equity
4,019 1,615 -767 -1,535 -2,218 -1,625 -1,372 -1,367 -1,392 -1,914 -1,394
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
4,019 1,615 -767 -1,535 -2,218 -1,625 -1,372 -1,367 -1,392 -1,914 -1,394
Common Stock
1,964 1,976 2,015 2,018 2,009 2,095 2,119 2,085 2,186 2,176 2,186
Retained Earnings
2,135 -299 -2,761 -3,543 -4,218 -3,707 -3,477 -3,431 -3,564 -4,080 -3,571
Accumulated Other Comprehensive Income / (Loss)
-73 -62 -21 -10 -9.00 -13 -14 -21 -14 -10 -9.00
Noncontrolling Interest
86 113 75 72 77 87 82 92 245 238 235

Quarterly Balance Sheets for Community Health Systems

This table presents Community Health Systems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
14,648 14,674 14,417 14,411 13,905 13,890 13,641 13,239 13,180 12,177 12,108
Total Current Assets
3,192 3,248 3,175 3,199 3,108 3,407 3,659 3,198 3,773 3,081 2,999
Cash & Equivalents
118 91 48 39 33 431 456 123 712 149 155
Accounts Receivable
2,043 2,160 2,194 2,195 2,043 2,326 2,261 2,159 2,139 2,143 2,102
Inventories, net
333 325 329 337 311 328 326 325 275 271 268
Prepaid Expenses
259 249 263 244 227 261 263 266 226 210 185
Current Deferred & Refundable Income Taxes
100 98 34 92 92 0.00 2.00 0.00 0.00 0.00 0.00
Other Current Assets
339 325 307 292 402 61 351 325 421 308 289
Plant, Property, & Equipment, net
5,250 5,160 5,219 5,222 4,964 4,742 4,657 4,620 4,201 4,183 4,236
Plant, Property & Equipment, gross
9,527 9,367 9,607 9,594 9,094 9,200 9,022 9,064 8,088 8,039 8,170
Accumulated Depreciation
4,277 4,207 4,388 4,372 4,130 4,458 4,365 4,444 3,887 3,856 3,934
Total Noncurrent Assets
6,206 6,266 6,023 5,990 5,833 5,741 5,325 5,421 5,206 4,913 4,873
Goodwill
4,054 3,943 3,957 3,972 3,940 3,785 3,604 3,540 3,130 3,228 3,233
Noncurrent Deferred & Refundable Income Taxes
49 49 29 29 29 13 13 75 29 35 36
Other Noncurrent Operating Assets
2,103 2,274 2,037 1,989 1,864 1,943 1,708 1,806 2,047 1,650 1,604
Total Liabilities & Shareholders' Equity
14,648 14,674 14,417 14,411 13,905 13,890 13,641 13,239 13,180 12,177 12,108
Total Liabilities
15,468 15,567 15,295 15,290 15,175 15,219 14,739 14,190 14,145 13,021 13,045
Total Current Liabilities
2,076 2,149 2,136 2,172 2,126 2,370 2,295 2,178 2,567 2,016 2,021
Short-Term Debt
30 22 34 27 20 29 23 16 29 26 18
Accounts Payable
736 837 941 896 842 974 970 894 790 713 831
Accrued Expenses
427 472 335 378 493 483 485 478 955 440 413
Current Deferred & Payable Income Tax Liabilities
- - - - - 96 - 3.00 53 74 55
Current Employee Benefit Liabilities
560 513 504 499 460 478 486 468 465 466 431
Other Current Liabilities
134 121 115 114 113 112 112 110 97 100 100
Other Current Nonoperating Liabilities
189 184 207 258 198 198 219 209 178 197 173
Total Noncurrent Liabilities
13,392 13,418 13,159 13,118 13,049 12,849 12,444 12,012 11,578 11,005 11,024
Long-Term Debt
11,728 11,820 11,533 11,504 11,467 11,303 10,840 10,589 10,127 9,552 9,568
Capital Lease Obligations
580 560 546 - 528 535 - 527 504 - 523
Noncurrent Deferred & Payable Income Tax Liabilities
362 344 354 351 239 205 240 30 25 25 25
Other Noncurrent Operating Liabilities
722 694 726 1,263 815 806 1,364 866 922 1,428 908
Redeemable Noncontrolling Interest
583 329 329 324 322 364 314 323 260 320 336
Total Equity & Noncontrolling Interests
-1,403 -1,222 -1,207 -1,203 -1,592 -1,693 -1,412 -1,274 -1,225 -1,164 -1,273
Total Preferred & Common Equity
-1,489 -1,463 -1,428 -1,441 -1,823 -1,923 -1,631 -1,502 -1,454 -1,390 -1,492
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-1,489 -1,463 -1,428 -1,441 -1,823 -1,923 -1,631 -1,502 -1,454 -1,390 -1,492
Common Stock
2,050 2,171 2,193 2,191 2,195 2,177 2,185 2,184 2,184 2,180 2,170
Retained Earnings
-3,520 -3,611 -3,605 -3,619 -4,010 -4,093 -3,811 -3,681 -3,628 -3,559 -3,644
Accumulated Other Comprehensive Income / (Loss)
-19 -23 -16 -13 -8.00 -7.00 -5.00 -5.00 -10 -11 -18
Noncontrolling Interest
86 241 221 238 231 230 219 228 229 226 219

Annual Metrics And Ratios for Community Health Systems

This table displays calculated financial ratios and metrics derived from Community Health Systems' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
4.65% -18.29% -16.73% -7.80% -6.68% -6.21% -0.18% -1.27% 2.28% 1.15% -1.18%
EBITDA Growth
-0.59% -90.44% -523.75% 189.28% 38.55% 33.86% 15.32% -24.10% -0.81% -29.69% 86.19%
EBIT Growth
-0.15% -164.32% -118.37% 111.08% 212.50% 73.23% 24.51% -32.95% 1.81% -43.36% 174.54%
NOPAT Growth
-5.73% -162.73% -118.37% 111.08% 212.50% 255.96% -36.16% -59.27% -82.43% 412.90% 266.20%
Net Income Growth
27.59% -727.80% -47.36% 70.62% 16.19% 202.88% -39.37% -51.36% -91.06% -2,362.50% 286.74%
EPS Growth
27.59% -1,234.31% -41.57% 68.23% 15.16% 174.03% -59.91% -80.11% -391.43% -282.35% 196.67%
Operating Cash Flow Growth
-42.97% 23.45% -32.01% -64.55% 40.51% 465.71% -106.01% 329.01% -30.00% 128.57% 13.13%
Free Cash Flow Firm Growth
109.32% 384.19% -18.80% -67.01% 49.35% 173.12% -124.53% 213.04% -74.71% 223.56% 157.27%
Invested Capital Growth
1.20% -18.64% -23.33% -5.72% -7.18% -17.91% 20.21% -5.28% -1.70% -4.31% -7.59%
Revenue Q/Q Growth
0.37% -15.62% 5.11% 2.88% -1.25% 3.63% -3.79% -0.75% 0.32% 0.66% -1.25%
EBITDA Q/Q Growth
-10.19% -31.03% -179.76% 182.40% 26.56% 17.52% -0.77% -4.60% 6.17% -3.93% 8.56%
EBIT Q/Q Growth
-17.98% -9.00% -638.11% 111.37% 76.15% 31.39% -0.92% -7.39% 11.67% -8.45% 12.98%
NOPAT Q/Q Growth
-13.63% -9.00% -638.11% 111.37% 76.15% 169.98% -2.13% 320.96% -92.28% -8.45% 22.32%
Net Income Q/Q Growth
-41.67% -10.24% -306.79% 70.81% -8.46% 774.44% -26.10% 489.13% -95.76% -45.38% 38.24%
EPS Q/Q Growth
-41.67% -8.82% -269.13% 68.10% -6.27% 0.00% 0.00% 123.81% -156.04% -29.57% 55.79%
Operating Cash Flow Q/Q Growth
-42.11% 1.88% -18.11% -54.03% 1,440.00% -5.14% -127.52% 225.00% 62.79% 35.59% 10.14%
Free Cash Flow Firm Q/Q Growth
-31.15% 2.11% 4.93% -29.24% 72.25% 17.62% -201.28% 166.91% -58.16% -23.68% 22.12%
Invested Capital Q/Q Growth
-0.94% -1.82% -13.05% -1.64% -4.75% -1.27% 16.82% -2.62% -7.04% -5.41% -7.11%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
46.30% 36.90% 34.55% 38.26% 38.70% 37.85% 41.11% 37.58% 40.69% 39.35% 41.72%
EBITDA Margin
11.13% 1.30% -6.62% 6.41% 9.52% 13.59% 15.70% 12.07% 11.71% 8.14% 15.33%
Operating Margin
5.93% -4.66% -12.23% 1.47% 4.92% 9.09% 11.34% 6.72% 7.66% 4.29% 11.92%
EBIT Margin
5.93% -4.66% -12.23% 1.47% 4.92% 9.09% 11.34% 7.70% 7.66% 4.29% 11.92%
Profit (Net Income) Margin
1.15% -8.82% -15.61% -4.97% -4.47% 4.90% 2.98% 1.47% 0.13% -2.87% 5.41%
Tax Burden Percent
63.02% 94.81% 84.57% 98.46% 137.21% 143.84% 73.75% 51.29% 7.73% 127.92% 93.37%
Interest Burden Percent
30.74% 199.42% 150.85% -343.75% -66.15% 37.48% 35.59% 37.13% 21.63% -52.21% 48.66%
Effective Tax Rate
28.22% 0.00% 0.00% 0.00% 0.00% -43.84% 26.25% 48.71% 92.27% 0.00% 6.63%
Return on Invested Capital (ROIC)
4.49% -3.09% -8.51% 1.12% 3.73% 15.15% 9.75% 3.73% 0.68% 3.60% 13.99%
ROIC Less NNEP Spread (ROIC-NNEP)
0.30% -9.48% -16.02% -5.13% -4.01% 6.74% 3.98% 1.72% 0.18% -2.78% 7.51%
Return on Net Nonoperating Assets (RNNOA)
1.09% -43.65% -217.85% 124.15% 41.69% -60.23% -49.23% -26.92% -2.73% 30.22% -76.76%
Return on Equity (ROE)
5.58% -46.74% -226.36% 125.27% 45.42% -45.08% -39.49% -23.19% -2.05% 33.82% -62.77%
Cash Return on Invested Capital (CROIC)
3.29% 17.47% 17.90% 7.00% 11.18% 34.83% -8.61% 9.15% 2.40% 8.00% 21.88%
Operating Return on Assets (OROA)
4.95% -3.54% -9.53% 1.25% 4.13% 7.12% 8.98% 6.29% 6.57% 3.80% 10.92%
Return on Assets (ROA)
0.96% -6.70% -12.16% -4.23% -3.75% 3.84% 2.36% 1.20% 0.11% -2.54% 4.96%
Return on Common Equity (ROCE)
4.81% -37.84% -90.67% 256.55% 65.61% -64.33% -63.49% -41.13% -3.64% 52.22% -96.39%
Return on Equity Simple (ROE_SIMPLE)
6.44% -100.68% 312.39% 45.86% 26.60% -37.35% -26.82% -13.09% -1.15% 18.91% 0.00%
Net Operating Profit after Tax (NOPAT)
960 -602 -1,315 146 455 1,620 1,034 421 74 379 1,389
NOPAT Margin
4.25% -3.27% -8.56% 1.03% 3.44% 13.07% 8.36% 3.45% 0.59% 3.00% 11.13%
Net Nonoperating Expense Percent (NNEP)
4.19% 6.39% 7.51% 6.25% 7.75% 8.41% 5.77% 2.01% 0.50% 6.38% 6.48%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 4.06% 0.72% 3.88% 15.04%
Cost of Revenue to Revenue
53.71% 63.10% 65.45% 61.74% 61.30% 62.16% 58.89% 62.42% 59.31% 60.65% 58.28%
SG&A Expenses to Revenue
20.03% 23.04% 25.17% 24.70% 25.00% 23.87% 23.92% 27.32% 27.13% 28.83% 27.42%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
40.37% 41.56% 46.79% 36.79% 33.78% 28.76% 29.77% 30.86% 33.03% 35.06% 29.80%
Earnings before Interest and Taxes (EBIT)
1,337 -860 -1,878 208 650 1,126 1,402 940 957 542 1,488
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,511 240 -1,017 908 1,258 1,684 1,942 1,474 1,462 1,028 1,914
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.78 0.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.14 0.03 0.03 0.02 0.03 0.07 0.14 0.05 0.03 0.03 0.03
Price to Earnings (P/E)
19.85 0.00 0.00 0.00 0.00 1.74 7.65 12.65 0.00 0.00 0.85
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
5.04% 0.00% 0.00% 0.00% 0.00% 57.49% 13.08% 7.90% 0.00% 0.00% 117.77%
Enterprise Value to Invested Capital (EV/IC)
0.95 0.93 1.08 1.13 1.20 1.25 1.25 1.16 1.15 1.20 1.17
Enterprise Value to Revenue (EV/Rev)
0.90 0.88 0.94 1.01 1.07 0.97 1.17 1.04 1.00 0.98 0.89
Enterprise Value to EBITDA (EV/EBITDA)
8.12 67.95 0.00 15.75 11.22 7.13 7.46 8.64 8.51 12.09 5.81
Enterprise Value to EBIT (EV/EBIT)
15.25 0.00 0.00 68.77 21.71 10.66 10.33 13.54 13.00 22.93 7.48
Enterprise Value to NOPAT (EV/NOPAT)
21.25 0.00 0.00 98.24 31.01 7.41 14.01 30.24 168.24 32.76 8.01
Enterprise Value to Operating Cash Flow (EV/OCF)
22.14 14.34 18.68 52.20 36.65 5.51 0.00 42.44 59.26 25.89 20.49
Enterprise Value to Free Cash Flow (EV/FCFF)
28.98 4.79 5.22 15.67 10.35 3.22 0.00 12.34 47.69 14.72 5.12
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
3.59 6.68 -84.32 -14.18 -8.18 -11.59 -15.65 -15.85 -13.94 -8.70 -12.42
Long-Term Debt to Equity
3.54 6.48 -84.12 -13.96 -8.17 -11.47 -15.61 -15.82 -13.92 -8.68 -12.40
Financial Leverage
3.60 4.60 13.60 -24.19 -10.39 -8.94 -12.38 -15.61 -14.96 -10.86 -10.22
Leverage Ratio
5.81 6.98 18.61 -29.63 -12.11 -11.74 -16.75 -19.36 -18.69 -13.32 -12.65
Compound Leverage Factor
1.79 13.91 28.07 101.87 8.01 -4.40 -5.96 -7.19 -4.04 6.95 -6.16
Debt to Total Capital
78.21% 86.98% 101.20% 107.59% 113.93% 109.44% 106.83% 106.73% 107.73% 112.99% 108.76%
Short-Term Debt to Total Capital
1.07% 2.60% 0.24% 1.61% 0.17% 1.10% 0.26% 0.19% 0.20% 0.20% 0.17%
Long-Term Debt to Total Capital
77.14% 84.38% 100.96% 105.97% 113.76% 108.34% 106.57% 106.54% 107.53% 112.80% 108.59%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
3.06% 3.81% 4.38% 4.56% 4.92% 5.12% 4.74% 5.81% 5.33% 5.89% 5.83%
Common Equity to Total Capital
18.73% 9.21% -5.58% -12.15% -18.85% -14.56% -11.56% -12.54% -13.05% -18.89% -14.58%
Debt to EBITDA
6.68 63.52 -13.68 14.97 10.66 7.25 6.53 7.89 7.86 11.14 5.43
Net Debt to EBITDA
6.61 62.53 -13.13 14.76 10.48 6.26 6.27 7.81 7.83 11.10 5.30
Long-Term Debt to EBITDA
6.59 61.62 -13.65 14.75 10.64 7.18 6.51 7.88 7.84 11.12 5.42
Debt to NOPAT
17.49 -25.32 -10.58 93.38 29.46 7.54 12.26 27.63 155.29 30.18 7.48
Net Debt to NOPAT
17.30 -24.93 -10.16 92.03 28.99 6.51 11.77 27.35 154.78 30.09 7.30
Long-Term Debt to NOPAT
17.25 -24.57 -10.56 91.98 29.42 7.47 12.23 27.58 155.01 30.13 7.47
Altman Z-Score
1.31 0.81 0.44 0.72 0.71 0.84 0.95 0.81 0.84 0.72 1.05
Noncontrolling Interest Sharing Ratio
13.65% 19.03% 59.94% -104.80% -44.46% -42.70% -60.78% -77.40% -77.09% -54.41% -53.57%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.68 1.62 1.73 1.48 1.50 1.60 1.47 1.41 1.50 1.41 1.46
Quick Ratio
1.24 1.18 1.25 1.07 1.08 1.28 1.09 0.99 1.06 0.99 1.06
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
704 3,407 2,766 913 1,363 3,723 -913 1,032 261 844 2,172
Operating Cash Flow to CapEx
98.19% 155.97% 138.78% 52.79% 88.51% 499.54% -28.54% 79.58% 47.84% 135.21% 166.06%
Free Cash Flow to Firm to Interest Expense
43.98 113.57 69.16 0.00 25.24 0.00 -11.56 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
57.56 37.90 19.33 0.00 7.13 0.00 -1.66 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-1.06 13.60 5.40 0.00 -0.93 0.00 -7.47 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.84 0.76 0.78 0.85 0.84 0.78 0.79 0.82 0.86 0.89 0.92
Accounts Receivable Turnover
6.43 5.43 5.52 5.98 5.73 5.92 6.20 5.95 5.85 5.59 5.72
Inventory Turnover
21.32 21.95 21.75 20.66 21.42 22.35 21.11 21.53 21.76 23.26 22.28
Fixed Asset Turnover
2.23 2.02 2.02 2.15 2.25 2.27 2.27 2.24 2.36 2.53 2.69
Accounts Payable Turnover
9.50 10.33 10.24 9.43 9.54 9.66 9.03 9.51 8.79 8.40 8.29
Days Sales Outstanding (DSO)
56.78 67.18 66.09 61.06 63.69 61.64 58.86 61.31 62.41 65.25 63.78
Days Inventory Outstanding (DIO)
17.12 16.63 16.78 17.67 17.04 16.33 17.29 16.95 16.78 15.69 16.38
Days Payable Outstanding (DPO)
38.42 35.34 35.64 38.72 38.27 37.78 40.41 38.38 41.51 43.46 44.02
Cash Conversion Cycle (CCC)
35.48 48.47 47.24 40.01 42.46 40.20 35.74 39.88 37.67 37.48 36.14
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
21,504 17,495 13,414 12,647 11,739 9,636 11,583 10,972 10,785 10,320 9,537
Invested Capital Turnover
1.06 0.95 0.99 1.09 1.08 1.16 1.17 1.08 1.15 1.20 1.26
Increase / (Decrease) in Invested Capital
256 -4,009 -4,081 -767 -908 -2,103 1,947 -611 -187 -465 -783
Enterprise Value (EV)
20,394 16,309 14,441 14,304 14,110 12,000 14,488 12,732 12,445 12,427 11,125
Market Capitalization
3,136 636 489 328 342 889 1,758 582 428 415 432
Book Value per Share
$34.01 $14.21 ($6.69) ($13.20) ($18.82) ($13.58) ($10.39) ($10.15) ($10.18) ($13.77) ($10.06)
Tangible Book Value per Share
($41.85) ($43.15) ($47.85) ($52.41) ($55.55) ($48.85) ($42.32) ($41.07) ($39.11) ($41.04) ($34.00)
Total Capital
21,461 17,526 13,748 12,637 11,766 11,162 11,865 10,901 10,663 10,135 9,559
Total Debt
16,785 15,244 13,913 13,596 13,405 12,216 12,675 11,635 11,487 11,452 10,396
Total Long-Term Debt
16,556 14,789 13,880 13,392 13,385 12,093 12,644 11,614 11,466 11,432 10,380
Net Debt
16,601 15,006 13,350 13,400 13,189 10,540 12,168 11,517 11,449 11,415 10,136
Capital Expenditures (CapEx)
938 729 557 519 435 436 459 377 439 355 327
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2,139 1,996 1,182 1,165 949 142 639 799 1,049 939 782
Debt-free Net Working Capital (DFNWC)
2,323 2,234 1,745 1,361 1,165 1,818 1,146 917 1,087 976 1,042
Net Working Capital (NWC)
2,094 1,779 1,712 1,157 1,145 1,695 1,115 896 1,066 956 1,026
Net Nonoperating Expense (NNE)
701 1,024 1,081 850 1,045 1,013 666 242 58 741 713
Net Nonoperating Obligations (NNO)
16,828 15,213 13,579 13,606 13,378 10,690 12,393 11,706 11,609 11,637 10,374
Total Depreciation and Amortization (D&A)
1,174 1,100 861 700 608 558 540 534 505 486 426
Debt-free, Cash-free Net Working Capital to Revenue
9.48% 10.83% 7.70% 8.23% 7.18% 1.15% 5.17% 6.54% 8.40% 7.43% 6.26%
Debt-free Net Working Capital to Revenue
10.30% 12.12% 11.37% 9.62% 8.82% 14.67% 9.27% 7.51% 8.70% 7.73% 8.35%
Net Working Capital to Revenue
9.28% 9.65% 11.15% 8.17% 8.67% 13.68% 9.02% 7.34% 8.53% 7.57% 8.22%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.14 ($15.54) ($22.00) ($6.99) ($5.93) $4.43 $1.82 $0.35 ($1.02) ($3.90) $3.81
Adjusted Weighted Average Basic Shares Outstanding
138.28M 110.73M 111.77M 112.73M 113.74M 115.49M 126.75M 128.81M 130.45M 132.10M 133.56M
Adjusted Diluted Earnings per Share
$1.13 ($15.54) ($22.00) ($6.99) ($5.93) $4.39 $1.76 $0.35 ($1.02) ($3.90) $3.77
Adjusted Weighted Average Diluted Shares Outstanding
139.27M 110.73M 111.77M 112.73M 113.74M 116.54M 130.60M 130.06M 130.45M 132.10M 135.01M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
136.24M 113.85M 114.63M 116.23M 117.86M 129.62M 132.12M 134.70M 136.74M 138.92M 138.63M
Normalized Net Operating Profit after Tax (NOPAT)
1,011 753 150 621 617 822 1,052 458 609 590 1,010
Normalized NOPAT Margin
4.48% 4.08% 0.98% 4.39% 4.67% 6.63% 8.50% 3.75% 4.88% 4.67% 8.09%
Pre Tax Income Margin
1.82% -9.30% -18.45% -5.05% -3.26% 3.41% 4.03% 2.86% 1.66% -2.24% 5.80%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
83.56 -28.67 -46.95 0.00 12.04 0.00 17.75 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
59.98 -20.07 -32.87 0.00 8.43 0.00 13.09 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
24.94 -52.97 -60.88 0.00 3.98 0.00 11.94 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
1.35 -44.37 -46.79 0.00 0.37 0.00 7.28 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
52.51% -6.83% -4.42% -18.04% -18.64% 19.28% 38.04% 72.63% 887.50% -43.65% 24.70%
Augmented Payout Ratio
113.90% -6.83% -4.42% -18.04% -18.64% 19.28% 38.04% 72.63% 887.50% -43.65% 24.70%

Quarterly Metrics And Ratios for Community Health Systems

This table displays calculated financial ratios and metrics derived from Community Health Systems' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - 140,306,440.00 140,119,116.00 - 138,625,756.00 140,916,712.00 141,009,357.00
DEI Adjusted Shares Outstanding
- - - - - 140,306,440.00 140,119,116.00 - 138,625,756.00 140,916,712.00 141,009,357.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - 2.01 0.93 - -0.42 0.50 -0.61
Growth Metrics
- - - - - - - - - - -
Revenue Growth
1.03% 0.80% 0.13% 2.61% 0.61% -0.22% -0.10% -4.84% -6.14% -9.83% -10.69%
EBITDA Growth
1.17% -1.36% -129.47% -9.35% 12.43% 69.78% 492.13% 37.10% 1.54% -19.58% -27.79%
EBIT Growth
10.00% -3.25% -218.50% -15.24% 22.94% 115.13% 218.54% 61.51% -1.06% -24.02% -39.92%
NOPAT Growth
91.00% 906.18% -218.50% -180.66% 268.21% 202.25% 218.54% 377.17% -203.58% -39.92% -39.92%
Net Income Growth
70.00% 1,200.00% -582.69% -131.40% 516.67% 1,130.77% 148.17% 692.59% -200.00% -67.50% -129.24%
EPS Growth
20.00% 65.52% -327.54% -247.22% 68.75% 2,190.00% 132.54% 254.72% -330.00% -75.60% -165.63%
Operating Cash Flow Growth
1,820.00% 17.44% 131.03% 140.00% 25.00% -12.87% 2.99% 23.15% -347.50% 0.00% 123.19%
Free Cash Flow Firm Growth
109.85% 1,211.97% 356.43% 4.61% 939.10% 103.99% 48.24% 218.67% -13.45% -43.46% 45.03%
Invested Capital Growth
-1.54% -6.20% -5.96% -4.31% -9.56% -12.35% -5.89% -7.59% -11.10% -7.83% -10.49%
Revenue Q/Q Growth
-1.29% 0.00% -1.59% 5.63% -3.22% -0.82% -1.47% 0.62% -4.54% -4.72% -2.41%
EBITDA Q/Q Growth
-22.94% 5.20% -124.45% 557.30% -4.42% 58.87% -43.53% 59.89% -29.21% 25.82% -49.30%
EBIT Q/Q Growth
-29.57% 3.03% -186.13% 235.61% 2.16% 80.28% -52.54% 84.77% -37.42% 38.43% -62.47%
NOPAT Q/Q Growth
-143.33% 296.44% -215.95% 18.27% 190.36% 252.99% -54.53% 91.10% -133.77% 304.76% -54.53%
Net Income Q/Q Growth
-106.98% 533.33% -1,465.38% 92.39% 192.59% 1,180.00% -46.56% -6.43% -115.63% 516.00% -148.08%
EPS Q/Q Growth
-188.89% 68.75% -2,850.00% 82.03% 81.13% 2,190.00% -54.07% -14.58% -152.44% 218.60% -223.53%
Operating Cash Flow Q/Q Growth
6.67% 5.21% -33.66% 222.39% -44.44% -26.67% -21.59% 285.51% -211.65% 129.63% 75.00%
Free Cash Flow Firm Q/Q Growth
-65.40% 631.97% -34.84% -36.61% 243.66% 43.69% -52.65% 36.28% -6.66% -6.14% 21.47%
Invested Capital Q/Q Growth
5.65% -4.59% 0.36% -5.41% -0.15% -7.54% 7.76% -7.11% -3.94% -4.14% 4.65%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
40.92% 39.97% 40.84% 35.82% 41.09% 42.67% 41.17% 41.95% 40.54% 42.02% 41.24%
EBITDA Margin
11.02% 11.59% -2.88% 12.47% 12.31% 19.73% 11.31% 17.97% 13.32% 17.59% 9.14%
Operating Margin
7.36% 7.58% -6.63% 8.52% 8.99% 16.34% 7.87% 14.46% 9.48% 13.77% 5.30%
EBIT Margin
7.36% 7.58% -6.63% 8.52% 8.99% 16.34% 7.87% 14.46% 9.48% 13.77% 5.30%
Profit (Net Income) Margin
-0.19% 0.83% -11.49% -0.83% 0.79% 10.21% 5.54% 5.15% -0.84% 3.68% -1.81%
Tax Burden Percent
-27.27% 52.00% 84.73% -42.19% 37.31% 73.06% -8,550.00% 72.40% -39.06% 57.78% 94.34%
Interest Burden Percent
9.52% 21.01% 204.39% 23.02% 23.59% 85.55% -0.82% 49.22% 22.78% 46.27% -36.30%
Effective Tax Rate
127.27% 48.00% 0.00% 142.19% 62.69% 26.94% 0.00% 27.60% 139.06% 42.22% 0.00%
Return on Invested Capital (ROIC)
-2.19% 4.40% -5.18% -4.30% 3.91% 14.80% 6.58% 13.16% -4.68% 10.41% 4.44%
ROIC Less NNEP Spread (ROIC-NNEP)
-1.73% 3.59% -6.89% -3.53% 3.23% 14.32% 6.59% 11.66% -3.90% 9.22% 3.01%
Return on Net Nonoperating Assets (RNNOA)
25.46% -51.11% 78.63% 38.27% -35.04% -162.08% -69.39% -119.16% 36.96% -96.16% -34.08%
Return on Equity (ROE)
23.28% -46.71% 73.45% 33.97% -31.13% -147.27% -62.81% -106.00% 32.28% -85.75% -29.64%
Cash Return on Invested Capital (CROIC)
2.70% 8.40% 9.83% 8.00% 13.88% 11.07% 16.80% 21.88% 25.00% 21.32% 17.04%
Operating Return on Assets (OROA)
6.34% 6.55% -5.83% 7.55% 8.04% 14.73% 7.33% 13.24% 8.61% 12.78% 4.87%
Return on Assets (ROA)
-0.16% 0.72% -10.09% -0.73% 0.71% 9.21% 5.16% 4.72% -0.77% 3.42% -1.67%
Return on Common Equity (ROCE)
40.07% -80.55% 111.59% 52.46% -47.26% -228.84% -94.04% -162.78% 47.52% -133.39% -47.00%
Return on Equity Simple (ROE_SIMPLE)
-2.10% -3.75% 13.66% 0.00% 17.21% 2.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-63 124 -144 -117 106 374 170 325 -110 225 102
NOPAT Margin
-2.01% 3.94% -4.64% -3.59% 3.35% 11.94% 5.51% 10.47% -3.70% 7.96% 3.71%
Net Nonoperating Expense Percent (NNEP)
-0.46% 0.81% 1.71% -0.78% 0.68% 0.48% -0.01% 1.50% -0.78% 1.19% 1.43%
Return On Investment Capital (ROIC_SIMPLE)
- - - -1.20% 1.04% 3.96% 1.73% 3.52% -1.16% 2.67% 1.16%
Cost of Revenue to Revenue
59.08% 60.03% 59.16% 64.19% 58.91% 57.33% 58.83% 58.05% 59.46% 57.98% 58.76%
SG&A Expenses to Revenue
26.91% 28.09% 32.69% 27.73% 27.38% 28.25% 26.95% 27.11% 27.93% 28.28% 29.34%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
33.57% 32.39% 47.48% 27.30% 32.10% 26.33% 33.30% 27.50% 31.06% 28.25% 35.94%
Earnings before Interest and Taxes (EBIT)
231 238 -205 278 284 512 243 449 281 389 146
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
346 364 -89 407 389 618 349 558 395 497 252
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.04 0.04 0.07 0.03 0.03 0.04 0.04 0.03 0.03 0.04 0.03
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 1.37 0.85 0.88 1.87 11.20
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 72.92% 117.77% 113.85% 53.54% 8.93%
Enterprise Value to Invested Capital (EV/IC)
1.15 1.15 1.23 1.20 1.20 1.20 1.17 1.17 1.18 1.19 1.19
Enterprise Value to Revenue (EV/Rev)
1.05 1.00 1.07 0.98 0.98 0.90 0.95 0.89 0.88 0.87 0.94
Enterprise Value to EBITDA (EV/EBITDA)
8.93 8.57 12.50 12.09 11.58 8.62 6.81 5.81 5.65 5.81 6.41
Enterprise Value to EBIT (EV/EBIT)
13.39 12.91 22.60 22.93 20.85 13.14 9.12 7.48 7.30 7.67 8.63
Enterprise Value to NOPAT (EV/NOPAT)
99.52 55.70 32.28 32.76 29.78 0.00 10.57 8.01 8.41 8.66 18.80
Enterprise Value to Operating Cash Flow (EV/OCF)
43.50 39.62 37.79 25.89 24.61 23.25 24.36 20.49 86.07 82.90 51.72
Enterprise Value to Free Cash Flow (EV/FCFF)
42.30 13.28 12.09 14.72 8.24 10.12 6.75 5.12 4.46 5.35 6.58
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-13.80 -13.12 -9.46 -8.70 -8.93 -9.89 -11.71 -12.42 -11.05 -11.35 -10.79
Long-Term Debt to Equity
-13.76 -13.09 -9.44 -8.68 -8.91 -9.87 -11.69 -12.40 -11.02 -11.32 -10.77
Financial Leverage
-14.76 -14.22 -11.41 -10.86 -10.83 -11.32 -10.53 -10.22 -9.49 -10.43 -11.31
Leverage Ratio
-17.40 -17.10 -13.21 -13.32 -12.83 -14.19 -12.22 -12.65 -11.80 -13.29 -13.43
Compound Leverage Factor
-1.66 -3.59 -27.01 -3.07 -3.03 -12.14 0.10 -6.23 -2.69 -6.15 4.87
Debt to Total Capital
107.81% 108.25% 111.82% 112.99% 112.61% 111.24% 109.34% 108.76% 109.95% 109.66% 110.22%
Short-Term Debt to Total Capital
0.30% 0.25% 0.19% 0.20% 0.28% 0.24% 0.16% 0.17% 0.30% 0.30% 0.20%
Long-Term Debt to Total Capital
107.51% 108.00% 111.63% 112.80% 112.34% 111.01% 109.18% 108.59% 109.65% 109.37% 110.02%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
4.90% 5.28% 5.15% 5.89% 5.64% 5.46% 5.41% 5.83% 5.04% 6.25% 6.05%
Common Equity to Total Capital
-12.71% -13.53% -16.97% -18.89% -18.25% -16.70% -14.75% -14.58% -15.00% -15.91% -16.27%
Debt to EBITDA
8.26 7.89 11.23 11.14 11.08 8.20 6.31 5.43 5.55 5.32 5.94
Net Debt to EBITDA
8.23 7.87 11.20 11.10 10.68 7.85 6.24 5.30 5.18 5.24 5.85
Long-Term Debt to EBITDA
8.24 7.87 11.21 11.12 11.05 8.18 6.31 5.42 5.54 5.31 5.93
Debt to NOPAT
92.07 51.29 28.99 30.18 28.49 -50.68 9.80 7.48 8.27 7.94 17.42
Net Debt to NOPAT
91.70 51.12 28.91 30.09 27.46 -48.55 9.69 7.30 7.72 7.82 17.15
Long-Term Debt to NOPAT
91.81 51.17 28.95 30.13 28.42 -50.57 9.79 7.47 8.25 7.92 17.39
Altman Z-Score
0.68 0.68 0.57 0.66 0.67 0.80 0.74 0.79 0.74 0.81 0.70
Noncontrolling Interest Sharing Ratio
-72.14% -72.45% -51.92% -54.41% -51.84% -55.39% -49.71% -53.57% -47.21% -55.56% -58.58%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.49 1.47 1.46 1.41 1.44 1.59 1.47 1.46 1.47 1.53 1.48
Quick Ratio
1.05 1.03 0.98 0.99 1.16 1.18 1.05 1.06 1.11 1.14 1.12
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
115 842 549 348 1,195 1,717 813 1,108 1,034 971 1,179
Operating Cash Flow to CapEx
104.35% 118.82% 97.10% 198.17% 141.18% 102.33% 111.29% 282.98% -390.79% 115.79% 177.01%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 347.72 0.00 0.00 24.64 138.51 129.28 194.15 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 216.00 0.00 0.00 2.09 33.25 -37.13 17.60 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 107.00 0.00 0.00 0.21 21.50 -46.63 2.40 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.86 0.86 0.88 0.89 0.89 0.90 0.93 0.92 0.91 0.93 0.92
Accounts Receivable Turnover
5.91 5.92 5.97 5.59 5.60 5.68 6.02 5.72 5.51 5.44 5.47
Inventory Turnover
21.69 21.95 23.13 23.26 23.35 23.09 24.03 22.28 23.81 23.52 23.02
Fixed Asset Turnover
2.39 2.40 2.48 2.53 2.54 2.56 2.64 2.69 2.75 2.71 2.63
Accounts Payable Turnover
8.84 9.01 8.76 8.40 8.01 8.20 8.80 8.29 8.14 8.34 7.91
Days Sales Outstanding (DSO)
61.75 61.64 61.11 65.25 65.19 64.31 60.66 63.78 66.30 67.07 66.73
Days Inventory Outstanding (DIO)
16.83 16.63 15.78 15.69 15.63 15.81 15.19 16.38 15.33 15.52 15.86
Days Payable Outstanding (DPO)
41.27 40.51 41.67 43.46 45.57 44.50 41.46 44.02 44.85 43.75 46.13
Cash Conversion Cycle (CCC)
37.31 37.77 35.23 37.48 35.26 35.62 34.38 36.14 36.78 38.84 36.46
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
11,394 10,871 10,910 10,320 10,305 9,528 10,267 9,537 9,161 8,782 9,190
Invested Capital Turnover
1.09 1.12 1.12 1.20 1.17 1.24 1.19 1.26 1.26 1.31 1.20
Increase / (Decrease) in Invested Capital
-178 -718 -692 -465 -1,089 -1,343 -643 -783 -1,144 -746 -1,077
Enterprise Value (EV)
13,094 12,521 13,378 12,427 12,405 11,417 12,010 11,125 10,845 10,446 10,912
Market Capitalization
479 467 843 415 375 477 450 432 408 471 403
Book Value per Share
($10.88) ($10.37) ($13.12) ($13.77) ($13.84) ($11.62) ($10.72) ($10.06) ($10.49) ($9.86) ($10.58)
Tangible Book Value per Share
($41.02) ($38.95) ($41.48) ($41.04) ($41.09) ($37.31) ($35.98) ($34.00) ($33.07) ($32.77) ($33.51)
Total Capital
11,235 10,652 10,745 10,135 10,538 9,765 10,181 9,559 9,695 8,734 9,172
Total Debt
12,113 11,531 12,015 11,452 11,867 10,863 11,132 10,396 10,660 9,578 10,109
Total Long-Term Debt
12,079 11,504 11,995 11,432 11,838 10,840 11,116 10,380 10,631 9,552 10,091
Net Debt
12,065 11,492 11,982 11,415 11,436 10,407 11,009 10,136 9,948 9,429 9,954
Capital Expenditures (CapEx)
92 85 69 109 85 86 62 94 76 76 87
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,025 1,015 969 939 635 931 913 782 523 942 841
Debt-free Net Working Capital (DFNWC)
1,073 1,054 1,002 976 1,066 1,387 1,036 1,042 1,235 1,091 996
Net Working Capital (NWC)
1,039 1,027 982 956 1,037 1,364 1,020 1,026 1,206 1,065 978
Net Nonoperating Expense (NNE)
-57 98 212 -90 81 54 -0.90 165 -85 121 152
Net Nonoperating Obligations (NNO)
12,272 11,750 12,180 11,637 11,634 10,626 11,218 10,374 10,126 9,626 10,127
Total Depreciation and Amortization (D&A)
115 126 116 129 105 106 106 109 114 108 106
Debt-free, Cash-free Net Working Capital to Revenue
8.19% 8.09% 7.72% 7.43% 5.02% 7.36% 7.22% 6.26% 4.26% 7.86% 7.22%
Debt-free Net Working Capital to Revenue
8.57% 8.40% 7.98% 7.73% 8.42% 10.97% 8.19% 8.35% 10.05% 9.10% 8.55%
Net Working Capital to Revenue
8.30% 8.19% 7.82% 7.57% 8.20% 10.79% 8.07% 8.22% 9.81% 8.89% 8.39%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.32) ($0.10) ($2.95) ($0.53) ($0.10) $2.11 $0.97 $0.83 ($0.43) $0.51 ($0.63)
Adjusted Weighted Average Basic Shares Outstanding
131.27M 132.34M 132.38M 132.10M 132.88M 133.76M 133.79M 133.56M 134.42M 135.49M 135.54M
Adjusted Diluted Earnings per Share
($0.32) ($0.10) ($2.95) ($0.53) ($0.10) $2.09 $0.96 $0.82 ($0.43) $0.51 ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding
131.27M 132.34M 132.38M 132.10M 132.88M 134.88M 135.19M 135.01M 134.42M 136.51M 135.54M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
138.97M 138.94M 138.95M 138.92M 140.31M 140.12M 138.52M 138.63M 140.92M 141.01M 141.03M
Normalized Net Operating Profit after Tax (NOPAT)
174 129 43 200 182 199 185 206 134 125 112
Normalized NOPAT Margin
5.53% 4.11% 1.40% 6.11% 5.76% 6.37% 5.99% 6.64% 4.51% 4.44% 4.06%
Pre Tax Income Margin
0.70% 1.59% -13.56% 1.96% 2.12% 13.98% -0.06% 7.12% 2.16% 6.37% -1.92%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 278.00 0.00 0.00 7.36 56.13 35.13 77.80 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 -117.28 0.00 0.00 5.15 40.63 -13.72 44.95 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 169.00 0.00 0.00 5.48 44.38 25.63 62.60 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 -226.28 0.00 0.00 3.28 28.88 -23.22 29.75 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
490.00% 266.67% -63.05% -43.65% -43.20% -454.05% 31.90% 24.70% 30.19% 39.27% 92.06%
Augmented Payout Ratio
490.00% 266.67% -63.05% -43.65% -43.20% -454.05% 31.90% 24.70% 30.19% 39.27% 92.06%

Financials Breakdown Chart

Key Financial Trends

Community Health Systems (NYSE: CYH) has shown a mixed financial trend across the available quarterly history. The company has improved from the severe losses reported in 2024, but its recovery remains uneven and is constrained by substantial debt, negative shareholder equity and volatile cash generation.

  • Q2 2026 returned to profitability. Consolidated net income was $104 million, compared with a $25 million loss in Q1 2026. Net income attributable to common shareholders was $70 million, or $0.51 per diluted share, versus a $58 million loss, or negative $0.43 per share, in Q1.
  • Operating cash flow recovered from the first-quarter outflow. Cash flow from operations improved from negative $297 million in Q1 2026 to positive $88 million in Q2. The latest quarter also matched the $88 million reported in Q2 2025, although this remains below the stronger quarterly levels seen in early 2025 and late 2025.
  • Debt reduction was significant in Q2. CYH repaid approximately $1.20 billion of debt while issuing $600 million of new debt, resulting in a net financing cash outflow of $628 million. Total reported liabilities fell to $13.02 billion from $14.15 billion in Q1 2026 and $14.74 billion in Q2 2025.
  • Divestitures continue to provide liquidity. CYH generated $110 million from divestitures in Q2 2026 and more than $1.1 billion in Q1. Asset sales have been an important source of cash as the company manages its debt obligations and operating needs.
  • Cost control has improved compared with earlier periods. Selling, general and administrative expense declined to $799 million in Q2 2026 from $885 million in Q2 2025 and $1.01 billion in Q3 2024. Depreciation expense also declined to $108 million from $126 million in Q2 2024.
  • Revenue remains large but is trending lower. Q2 2026 revenue was $2.83 billion, down from $2.97 billion in Q1 2026 and $3.13 billion in Q2 2025. Revenue has generally remained in the $3.0 billion-to-$3.3 billion range over the available four-year period, but the recent decline suggests investors should monitor patient volumes, reimbursement and hospital-level performance.
  • Cash flow remains highly dependent on working capital and asset transactions. Operating cash flow ranged from negative $297 million in Q1 2026 to positive $266 million in Q4 2025 and positive $120 million in Q1 2025. Investing cash flow has also varied widely because of divestitures, making the reported cash balance less representative of recurring free cash generation.
  • Q2 profitability was substantially below the prior-year quarter. Net income attributable to common shareholders fell from $282 million in Q2 2025 to $70 million in Q2 2026, while diluted EPS declined from $2.09 to $0.51. The company also reported a lower operating margin of roughly 13.8%, compared with approximately 16.3% a year earlier.
  • Liquidity weakened sharply during Q2. Cash and equivalents declined from $712 million at March 31, 2026, to $149 million at June 30, 2026, after debt repayments, dividends and other cash uses. Although current assets exceeded current liabilities, the cash balance is small relative to the company’s debt obligations and quarterly cash interest payments of $176 million.
  • CYH continues to have negative common equity and elevated leverage. Common equity was negative $1.39 billion at the end of Q2 2026, while long-term debt stood at $9.55 billion. Negative retained earnings have persisted throughout the available history, and goodwill remained substantial at $3.23 billion, increasing the importance of future operating performance and impairment risk.

For investors, the main improvement is that CYH has moved back to positive earnings and operating cash flow after the loss reported in Q1 2026. However, the year-over-year decline in revenue and earnings, the sharp reduction in cash, high interest burden and negative equity indicate that the company’s financial recovery is still fragile. Continued debt reduction and consistently positive operating cash flow will be important to support a more durable improvement in the stock’s outlook.

11/21/26 06:07 PM ETAI Generated. May Contain Errors.

Community Health Systems Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Community Health Systems' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Community Health Systems' net income appears to be on an upward trend, with a most recent value of $676 million in 2025, rising from $259 million in 2015. The previous period was -$362 million in 2024. Find out what analysts predict for Community Health Systems in the coming months.

Community Health Systems' total operating income in 2025 was $1.49 billion, based on the following breakdown:
  • Total Gross Profit: $5.21 billion
  • Total Operating Expenses: $3.72 billion

Over the last 10 years, Community Health Systems' total revenue changed from $22.56 billion in 2015 to $12.49 billion in 2025, a change of -44.7%.

In the past 13 quarters, Community Health Systems' cash and equivalents has ranged from $33 million in Q3 2024 to $712 million in Q1 2026, and is currently $155 million as of their latest financial filing in Q3 2026.

Community Health Systems had total debt of $10.40 billion at the end of 2025, a 9.2% decrease from 2024, and a 38.1% decrease since 2015.

Over the last 10 years, Community Health Systems' book value per share changed from 34.01 in 2015 to -10.06 in 2025.



Financial statements for NYSE:CYH last updated on 10/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners